|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
9 weeks of herceptin may be as good as 52 (but problems with this study)
Study was retrospective, not prospective
groups receiving 9 vs 52 weeks were not matched for characteristics, rather gleaned after the fact from medical records registered
reasons for giving 9 wks to some vs 52 wks to others not yet elucidated (ie, what criteria were used--oncologist's preference, patient's economic circumstances, etc)
Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
Sub-category:
HER2+
Category:
Breast Cancer - HER2/ER
Meeting:
2011 ASCO Annual Meeting
Abstract No:
629
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 629)
Attend this session at the
ASCO Annual Meeting!
Session: Breast Cancer - HER2/ER
Type: General Poster Session
Time: Monday June 6, 1:00 PM to 5:00 PM
Location: McCormick Place Hall A
Personalize your Annual Meeting experience with a suggested or customized itinerary!
Author(s): F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu, Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas, N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren, Turkish Oncology Group; Ankara University School of Medicine, Ankara, Turkey; Hacettepe University Medical School, Ankara, Turkey; Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey; Cukurova University Scool of Medicine, Adana, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey; Erciyes University Medical School, Kayseri, Turkey; Ege University Hospital, Izmir, Turkey; Gaziantep University, Gaziantep, Turkey; Ankara University Medical School, Ankara, Turkey; Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey; Ege University, Izmir, Turkey; Ankara Hospital, Ankara, Turkey; Department of Medical Oncology, Bayindir Hospital, Ankara, Turkey; Dicle University, Diyarbakir, Turkey; Ege Unversity Medical School, Tulay Aktas Oncology Hospital, Izmir, Turkey; Kocaeli University Medical School, Kocaeli, Turkey; Department of Medical Oncology, Eskisehir Osmangazi University, Eskisehir, Turkey; Pamukkale University Medical School, Denizli, Turkey
Abstract Disclosures
Abstract:
Background: Adjuvant trastuzumab (T) improves DFS in early breast cancer. However the optimal duration of adjuvant T is under debate. Some of the oncologists in Turkey prefer to give 9 weeks of adjuvant T for several reasons. Turkish Oncology Group decided to compare the outcome of 9 weeks and 52 weeks of adjuvant T in an observational study. Methods: Names of the patients with c-ErbB2:3+ or FISH positive disease who were registered to receive adjuvant T were obtained from Ministry of Health.The records of 690 patients who received adjuvant T beginning from November 2006 to December 2009 were reached and follow-up were obtained from their oncologists. Nine weeks and up to 52 weeks of T was given to 204 and 486 patients respectively. In 34 out of 486 patients T was stopped before 52 weeks for several reasons other than toxicity and disease progression. Results: Patient characteristics are shown in the table. Median follow-up from initiation of T was 22 months. While no cardiac toxicity causing interruption T was observed in the 9 weeks T group, it was 3.3% in the >9 weeks T group. Disease-free survival (DFS) at 2 years was 85.6% and 85.4% in 9 weeks and >9 weeks groups respectively. According to unadjusted Cox regression analysis HR was 0.934 (95 %CI:0.552-1.580; p:0.28). Analysis with adjusted cox regression gave a HR of 0.727 (95 %CI:0.408-1.295;p:0.28). Conclusions: No significant inferiority for 9 weeks of adjuvant T when compared to longer duration was observed at this time. Follow-up at 3 and 5 years were planned.
|
Linear Mode
